Mainz Biomed B.V. (MYNZ)
USD 3.14
(-0.32%)
USD 3.14
(-0.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 12.15 Million USD | 97.88% |
| 2022 | 6.14 Million USD | 67.0% |
| 2021 | 3.67 Million USD | 7.75% |
| 2020 | 3.41 Million USD | 28.08% |
| 2019 | 2.66 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q4 | 12.15 Million USD | -15.89% |
| 2023 Q2 | 14.12 Million USD | 43.28% |
| 2023 Q1 | 9.86 Million USD | 60.46% |
| 2023 Q3 | 14.45 Million USD | 2.33% |
| 2023 FY | 12.15 Million USD | 97.88% |
| 2022 Q2 | 3.84 Million USD | 0.0% |
| 2022 Q4 | 6.14 Million USD | 0.0% |
| 2022 FY | 6.14 Million USD | 67.0% |
| 2021 Q1 | 39.99 Thousand USD | -98.83% |
| 2021 FY | 3.67 Million USD | 7.75% |
| 2021 Q3 | 919.91 Thousand USD | -70.76% |
| 2021 Q4 | 3.67 Million USD | 300.0% |
| 2021 Q2 | 3.14 Million USD | 7767.94% |
| 2020 FY | 3.41 Million USD | 28.08% |
| 2020 Q4 | 3.41 Million USD | 300.0% |
| 2020 Q3 | 853.7 Thousand USD | 0.0% |
| 2020 Q2 | 853.7 Thousand USD | 0.0% |
| 2020 Q1 | 853.7 Thousand USD | 28.08% |
| 2019 FY | 2.66 Million USD | 0.0% |
| 2019 Q4 | 666.56 Thousand USD | 0.0% |
| 2019 Q1 | 666.56 Thousand USD | 0.0% |
| 2019 Q2 | 666.56 Thousand USD | 0.0% |
| 2019 Q3 | 666.56 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 69.771% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -38.508% |
| Aspira Women's Health Inc. | 8.62 Million USD | -40.951% |
| Biodesix, Inc. | 94.51 Million USD | 87.135% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -598.06% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -261.222% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -261.222% |
| Bionano Genomics, Inc. | 118.24 Million USD | 89.717% |
| CareDx, Inc | 223.28 Million USD | 94.554% |
| Check-Cap Ltd. | 1.33 Million USD | -814.271% |
| Castle Biosciences, Inc. | 86.54 Million USD | 85.949% |
| DarioHealth Corp. | 38.24 Million USD | 68.206% |
| Exact Sciences Corporation | 3.32 Billion USD | 99.634% |
| Fulgent Genetics, Inc. | 139.82 Million USD | 91.303% |
| Guardant Health, Inc. | 1.62 Billion USD | 99.253% |
| ICON Public Limited Company | 7.74 Billion USD | 99.843% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 99.315% |
| Illumina, Inc. | 4.36 Billion USD | 99.721% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -117.307% |
| iSpecimen Inc. | 6.07 Million USD | -100.061% |
| Standard BioTools Inc. | 159.86 Million USD | 92.394% |
| MDxHealth SA | 121.92 Million USD | 90.027% |
| 23andMe Holding Co. | 206.64 Million USD | 94.116% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 98.892% |
| Myriad Genetics, Inc. | 312.9 Million USD | 96.114% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -1010.325% |
| NeoGenomics, Inc. | 739.69 Million USD | 98.356% |
| Neogen Corporation | 1.44 Billion USD | 99.156% |
| Inotiv, Inc. | 588.04 Million USD | 97.932% |
| Natera, Inc. | 691.79 Million USD | 98.242% |
| OpGen, Inc. | 13.44 Million USD | 9.551% |
| OPKO Health, Inc. | 622.47 Million USD | 98.047% |
| Psychemedics Corporation | 6.59 Million USD | -84.295% |
| Prenetics Global Limited | 44.01 Million USD | 72.372% |
| Prenetics Global Limited | 44.01 Million USD | 72.372% |
| Precipio, Inc. | 3.67 Million USD | -231.149% |
| Personalis, Inc. | 95.65 Million USD | 87.288% |
| RadNet, Inc. | 2.07 Billion USD | 99.414% |
| Sera Prognostics, Inc. | 25.28 Million USD | 51.905% |
| Sotera Health Company | 2.68 Billion USD | 99.547% |
| Neuronetics, Inc. | 81.64 Million USD | 85.106% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 43.899% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 43.899% |
| Trinity Biotech plc | 83.38 Million USD | 85.417% |
| T2 Biosystems, Inc. | 62.83 Million USD | 80.647% |
| Twist Bioscience Corporation | 152.97 Million USD | 92.051% |
| Exagen Inc. | 34.25 Million USD | 64.497% |